Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The historical rank and industry rank for Mauna Kea Technologies's FCF Margin % or its related term are showing as below:
XPAR:ALMKT'
s FCF Margin % Range Over the Past 10 Years
Min: -179.79 Med: -129.5 Max: -10.83
Current: -47.31
During the past 13 years, the highest FCF Margin % of Mauna Kea Technologies was -10.83%. The lowest was -179.79%. And the median was -129.50%.
XPAR:ALMKT's FCF Margin % is ranked worse than 78.53% of 815
companies
in the Medical Devices & Instruments industry
Industry Median: -0.64
vs XPAR:ALMKT: -47.31
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XPAR:ALMKT vs ABT, SYK, MDT: FCF Margin % Comparison
For the Medical Devices subindustry, Mauna Kea Technologies's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Mauna Kea Technologies FCF Margin % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Mauna Kea Technologies's FCF Margin % distribution charts can be found below:
* The bar in red indicates where Mauna Kea Technologies's FCF Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Mauna Kea Technologies (XPAR:ALMKT) has a FCF Margin % of -36.52% as of Dec. 2025. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Mauna Kea Technologies and its competitors. According to the industry distribution chart, Mauna Kea Technologies ranks #640 out of 815 companies in the Medical Devices & Instruments industry, placing it in the top 78.5%.
Is Mauna Kea Technologies' FCF Margin % too high?
Mauna Kea Technologies' current FCF Margin % is -36.52%. Based on the distribution chart, Mauna Kea Technologies ranks #640 out of 815 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Mauna Kea Technologies has a GF Score™ of 39/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Mauna Kea Technologies' FCF Margin % compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Mauna Kea Technologies ranks #640 out of 815 companies for FCF Margin %. This places Mauna Kea Technologies in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Margin % for a Medical Devices & Instruments company?
A good FCF Margin % depends on the Medical Devices & Instruments industry context. However, FCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Margin % mean?
A high FCF Margin % can signal that a stock is expensive relative to its fundamentals. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Mauna Kea Technologies and its competitors. Mauna Kea Technologies's current FCF Margin % is -36.52%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Mauna Kea Technologies stock overvalued right now?
Based on GuruFocus' analysis, Mauna Kea Technologies (XPAR:ALMKT) is currently considered Fairly Valued. The stock's GF Value™ is €0.14, compared to a current price of €0.15 — trading 10% above its estimated fair value. The current FCF Margin % is -36.52%. Mauna Kea Technologies' overall GF Score™ is 39/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Margin % calculated?
FCF Margin % is calculated from a company's financial statements. For Mauna Kea Technologies (XPAR:ALMKT), the current FCF Margin % is -36.52% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Mauna Kea Technologies (XPAR:ALMKT) Overvalued in 2026?
Based on GuruFocus' analysis, Mauna Kea Technologies stock appears to be overvalued.
The current stock price of €0.15 is trading 10% above its estimated GF Value™ of €0.14.
GuruFocus considers Mauna Kea Technologies to be Fairly Valued.
Key valuation signals for XPAR:ALMKT:
FCF Margin %: -36.52%
GF Value™: €0.14 vs. price of €0.15 (10% above fair value)
No single metric tells the full story. See the XPAR:ALMKT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Mauna Kea Technologies SA is a medical device company that develops, manufactures and markets an imaging platform for visualizing tissue at the cellular level, in real time, during standard procedures, with the mission of eliminating uncertainties in diagnosis and treatment through direct visualization of tissue in vivo at the microscopic level. The company's flagship product, Cellvizio, is the smallest microscope, designed for direct use during minimally invasive procedures. It operates in a single business segment: endomicroscopy. Its geographical presence includes EMEA (Europe, Middle East, Africa), USA and Canada, and Asia, of which the majority of the revenue is generated from USA and Canada.
39GF Score
Get the complete analysis for XPAR:ALMKT
FCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XPAR:ALMKT has been successfully added to your 
